Literature DB >> 28604419

Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.

Ciro D Soares1, Camilla F Borges, Marcondes Sena-Filho, Oslei P de Almeida, Rafael F Stelini, Maria L Cintra, Edgard Graner, Karina G Zecchin, Jacks Jorge.   

Abstract

Cyclooxygenase 2 (COX-2) and phosphorylated Akt1 (p-Akt1) are associated with tumor spreading, cell proliferation, high metabolism, and angiogenesis in solid tumors. This study aimed to investigate COX-2 and p-Akt1 expression in primary and metastatic melanomas by correlating with the cellular proliferation index (as revealed by minichromosome maintenance 2 expression) and the outcome of patients with malignant melanomas. Seventy-seven biopsies of malignant melanomas, including 42 primary nonmetastatic melanomas (PNMMs), 12 primary metastatic melanomas (PMMs), and 23 metastatic melanomas (MMs), were retrospectively selected. Tissue microarrays were developed and submitted for immunohistochemical staining for COX-2, p-Akt1, and minichromosome maintenance 2. Increased COX-2 cytoplasmic staining patterns were observed in PMM and MM when compared with PNMM (P=0.0011). Higher nuclear and cytoplasmic expression of p-Akt1 was more closely associated with PMM than with MM and PNMM (P<0.00001). Coexpression of these biomarkers was closely correlated with lower overall survival rates in melanomas. Furthermore, we observed a statistically significant positive correlation between the mitosis index and increased COX-2 expression (P=0.0135) and between p-Akt1 (P=0.0038) and the cellular proliferation index (P=0.0060). Taken together, our findings demonstrate that COX-2 and p-Akt1 play an important combined role during melanoma progression and are associated with highly metastatic tumors and survival rates in patients with MM. In addition, these biomarkers can be used to predict melanoma prognosis independently of metastatic status. However, further studies are required to elucidate the biological role of these biomarkers during the progression of MM events.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28604419     DOI: 10.1097/CMR.0000000000000368

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  9 in total

1.  Phosphorylation-dependent substrate selectivity of protein kinase B (AKT1).

Authors:  Nileeka Balasuriya; Norman E Davey; Jared L Johnson; Huadong Liu; Kyle K Biggar; Lewis C Cantley; Shawn Shun-Cheng Li; Patrick O'Donoghue
Journal:  J Biol Chem       Date:  2020-04-29       Impact factor: 5.157

2.  Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.

Authors:  Kelly E Regan-Fendt; Jielin Xu; Mallory DiVincenzo; Megan C Duggan; Reena Shakya; Ryejung Na; William E Carson; Philip R O Payne; Fuhai Li
Journal:  NPJ Syst Biol Appl       Date:  2019-02-26

3.  Integrative Analysis of Minichromosome Maintenance Proteins and Their Prognostic Significance in Melanoma.

Authors:  Wei Han; Yi-Zhu Wu; Xiao-Yu Zhao; Zhen-Hua Gong; Guo-Liang Shen
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 6.244

Review 4.  COX-2 as a potential biomarker and therapeutic target in melanoma.

Authors:  Diana Valentina Tudor; Ioana Bâldea; Mihai Lupu; Teodor Kacso; Eniko Kutasi; Andreea Hopârtean; Roland Stretea; Adriana Gabriela Filip
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

5.  Network Pharmacology Study on the Pharmacological Mechanism of Cinobufotalin Injection against Lung Cancer.

Authors:  Yun Mao; Xi Peng; Peng Xue; Dianrong Lu; Linlu Li; Shijie Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-17       Impact factor: 2.629

Review 6.  Alternative Options for Skin Cancer Therapy via Regulation of AKT and Related Signaling Pathways.

Authors:  Sun-Young Hwang; Jung-Il Chae; Ah-Won Kwak; Mee-Hyun Lee; Jung-Hyun Shim
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

Review 7.  Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy.

Authors:  Yanni Ma; Ronghui Xia; Xuhui Ma; Robert L Judson-Torres; Hanlin Zeng
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

8.  Low Blue Dose Photodynamic Therapy with Porphyrin-Iron Oxide Nanoparticles Complexes: In Vitro Study on Human Melanoma Cells.

Authors:  Simona Nistorescu; Ana-Maria Udrea; Madalina Andreea Badea; Iulia Lungu; Mihai Boni; Tatiana Tozar; Florian Dumitrache; Valentin-Adrian Maraloiu; Roua Gabriela Popescu; Claudiu Fleaca; Ecaterina Andronescu; Anca Dinischiotu; Angela Staicu; Mihaela Balas
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

9.  miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.

Authors:  Elisabetta Vergani; Matteo Dugo; Mara Cossa; Monica Rodolfo; Viviana Vallacchi; Simona Frigerio; Lorenza Di Guardo; Gianfrancesco Gallino; Ilaria Mattavelli; Barbara Vergani; Luca Lalli; Elena Tamborini; Barbara Valeri; Chiara Gargiuli; Eriomina Shahaj; Marina Ferrarini; Elisabetta Ferrero; Macarena Gomez Lira; Veronica Huber; Michele Del Vecchio; Marialuisa Sensi; Biagio Eugenio Leone; Mario Santinami; Licia Rivoltini
Journal:  Cell Commun Signal       Date:  2020-09-23       Impact factor: 7.525

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.